60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Gross-Profit-to-Asset % : 2.52% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. 60 Degrees Pharmaceuticals's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.20 Mil. 60 Degrees Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2024 was $8.08 Mil. Therefore, 60 Degrees Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 2.52%.

60 Degrees Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Gross-Profit-to-Asset % Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

56.72

15.50

-15.53

-4.87

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							-5.04	-6.64	-0.97	-0.99	2.52

Competitive Comparison of 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset % falls into.

60 Degrees Pharmaceuticals Gross-Profit-to-Asset % Calculation

60 Degrees Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	-0.221	/	( (1.297	+	7.784)	/ 2 )
	=	-0.221	/	4.5405
	=	-4.87 %

60 Degrees Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0.204	/	( (7.784	+	8.379)	/ 2 )
	=	0.204	/	8.0815
	=	2.52 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

60 Degrees Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SXTP:USA

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.